Pharmacist Advanced Training Microcredentials | Pharmacogenomics On-Demand 8 credit hours

Discover how personalized medicine can have an impact on patient outcomes with our comprehensive pharmacogenomics training course for pharmacists. Gain a better understanding of the intricate relationship between genetics and drug response, explore cutting-edge research, review how genetic variations affect drug metabolism, and discuss practical insights for implementing pharmacogenomics into pharmacy practice. Revolutionize your pharmacy career by mastering the science behind pharmacogenomics to provide individualized care and optimize patient outcomes.

Pharmacogenomics - Pharmacist

Claim Your Badge

You will receive an email from Credly (our credential partner), after you complete the course, inviting you to claim your digital badge for Pharmacogenomics - Pharmacist. This will allow you to easily share your achievement with colleagues, managers, and your professional network on LinkedIn and other platforms. When you receive the email, please click the button and create an account on Credly.com so that you can “accept” the badge.

Need help? Find a step-by-step tutorial video at this link.

Learning Objectives

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Describe the pharmacists’ role in pharmacogenomics (PGx).
2. Discuss the state of PGx implementations across the industry.
3. Recognize basic mechanisms for genetic variation to impact medications.
4. Describe the standard nomenclature used in PGx.
5. Compare and contrast different types of genetic tests.
6. Provide specific examples that establish the relationship between altered drug disposition and genetic variants.
7. Describe how PGx can be utilized to predict an individual’s response to drug therapy.
8. Detail ethical, legal, and social issues (ELSI) and regulatory concerns surrounding PGx testing.
9. Review regulatory activity, especially FDA guidance and rulemaking, impacting PGx.
10. Describe the potential limitations of PGx testing.
11. Describe the role of various PGX resources available to support clinical application.
12. Discuss strategies to identify whether a drug-gene pair is ready for clinical use.
13. Recognize the value that PGx can bring to patient care.
14. Develop a pharmacotherapy regimen based on patient PGX results and characteristics.
15. Create PGx therapeutic guidelines for selected drugs using a specified framework.
16. Utilize clinical decision support tools to inform therapeutic recommendations.
17. Apply guidelines and other evidence to patient cases across multiple medical specialties and subspecialities (e.g., behavioral health, cardiology, oncology, pain management).
18. Identify the impact of ancestry on PGx variant frequencies.
19. Discuss the roles and responsibilities of clinical laboratories.
20. Describe criteria for selecting a PGx laboratory.
21. Compare and contrast provider-ordered clinical PGx lab testing vs direct-to-consumer genetic testing.
22. Detail the key components required in a PGx test for clinical practice.
23. Describe utilization of PGx in terms relevant for healthcare providers and payors.
24. Identify strategies to develop and deliver PGx recommendations to prescribers.
25. Explain genetic testing and its role in health care to patient.
26. Describe important counseling points for PGx testing.

Activities

1. Applying Pharmacogenomics to Patient Care – Our Current State
2. Genetics 101
3. Regulatory Review – Impact on Pharmacogenomics
4. Gene Information
5. Application to Practice – Opioids
6. From Phenotype to Drug Selection
7. Case-Based Application of Pharmacogenomics
8. Choosing a Laboratory Partner
9. Explaining Pharmacogenomic Results to Healthcare Providers
10. Explaining Pharmacogenomic Results to Patients

Faculty

John A. Galdo, PharmD, MBA, BCPS, BCGP

Disclosures:

Jake Galdo reports that his wife is employed by Eli Lilly and is a former employee of Prime Therapeutics. He is CEO of Seguridad, Inc. and Managing Network Facilitator of CPESN Health Equity. All relevant financial relationships have been mitigated.

D. Max Smith, PharmD, BCPS

Disclosures:

D. Max Smith has no relevant financial relationships with ineligible companies to disclose.

Emily Loudermilk, PharmD, MS Pharmacogenomics, BCPS

Disclosures:

Emily Loudermilk has no relevant financial relationships with ineligible companies to disclose.

Behnaz Sarrami, MS, PharmD, PGx Certification

Disclosures:

Behnaz Sarrami is a Consultant for Missouri Pharmacogenomics Consulting, LLC. All relevant financial relationships have been mitigated.

Sarah Mills, PharmD, BCPS

Disclosures:

Sarah Mills has no relevant financial relationships with ineligible companies to disclose.

Course Details